Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Indian Pharma Bets Beyond US Generics
Companies are investing heavily in complex injectables, respiratory therapies and biosimilars to improve margins and diversify portfolios. Indian pharmaceutical companies are increasingly shifting their growth focus beyond the traditional US…
ARS Pharma: Strong Growth Meets A Coverage Wall (NASDAQ:SPRY)
ARS Pharmaceuticals is rated a hold due to heightened near-term execution risk despite a compelling long-term Neffy opportunity. SPRY's Q1 revenue nearly tripled to $22.7M, but aggressive SG&A spending drove a $60.6M net loss and elevated cash…
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
Investors seeking reliable dividends often look to the healthcare sector, but choosing between AbbVie Inc (ABBV +3.72%) and Pfizer Inc (PFE 1.70%) requires a close look at their post-pandemic growth strategies and pipelines. AbbVie focuses on…
Alembic Pharma gets USFDA final approval for Oseltamivir oral suspension
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Oseltamivir Phosphate for Oral Suspension, 6 mg/mL. The approved ANDA is therapeutically…
3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree
Large-cap pharma is back in the deal market. AbbVie's (NASDAQ: ABBV | ABBV Price Prediction) pending acquisition of Apogee Therapeutics signaled that big buyers will pay up for de-risked clinical assets. Patent cliffs approach, GLP-1 franchises…
Royalty Pharma (NASDAQ:RPRX) EVP Sells 9,098 Shares
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 9,098 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $55.18, for a total transaction of $502,027.64. Following the…
Barton Investment Management Makes New Investment in Royalty Pharma PLC $RPRX
Barton Investment Management bought a new stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 18,875 shares of the…
Merck KGaA Agrees on $11.3 Billion Purchase of Bio-Techne
Merck KGaA agreed to buy Bio-Techne Corporation for $11.3 billion to bolster its life-science business, marking the German pharma and technology group's biggest acquisition in more than a decade. Merck agreed to pay $73 per share in cash for the US…
Inside the Lilly CEO's Plan to Build on Its $1 Trillion Weight-Loss Empire
This article is for subscribers only. Welcome back to Bloomberg's Health Monitor, a weekly look at the boardroom decisions, scientific advances and policy fights shaping the future of medicine. Sign up now if you're not already on the list. Lilly's…
British American Tobacco Stock: Not Simply Philip Morris' Lagging Sibling (NYSE:BTI)
British American Tobacco is rated as a Sell due to unclear growth in its Vapour and Heated Product segments, margin dilution, and regulatory headwinds despite a ~5.4% dividend yield. BTI's Modern Oral segment has shown strong growth and is…
Germany's Merck boosts life sciences business with $11 billion Bio-Techne deal
Arne Dedert | Picture Alliance | Getty Images German drugmaker Merck KGaA said on Thursday it will acquire U.S. biotech firm Bio-Techne for $11.3 billion, expanding its presence in the life sciences market. Shares of Bio-Techne rose 22% in…
Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity (NASDAQ:SNY)
Sanofi is reiterated as a compelling buy, trading at a pronounced valuation discount versus pharma peers despite solid results and strategic focus. Dupixent drives 40% of Sanofi's sales and 80% of Q1 incremental growth; management is pursuing…
Is GSK Quietly Becoming An Oncology Powerhouse (NYSE:GSK)
GSK's dividend yield is 3.46%, which is higher than most Big Pharma players. GSK reaffirmed that its core earnings per share growth will be between 7% and 9% in 2026. In addition to the strong performance of its blockbusters, Nucala, Dovato, and…
Cursor Deal Puts US On Track For Record Startup M&A Year
When someone spends $60 billion to buy a startup, M&A spending suddenly starts looking pretty robust. Those were the unsurprising findings of a Crunchbase analysis of U.S. startup acquisition outlays in 2026. So far this year, acquirers have spent…
An Analyst Just Declared Eli Lilly the 'Clear Winner' of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?
In the eyes of Wall Street, Eli Lilly (LLY +2.19%) continues to cement its lead over the competition in the field of weight-loss and diabetes drugs. After revealing a pair of positive developments coinciding with the American Diabetes Association's…
Receive a Daily briefing on Pharma Industry News
Get Started